GO:2000753 positive regulation of glucosylceramide catabolic process: Sphingolipid Catabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000753 describes any process that activates or increases the frequency, rate or extent of glucosylceramide catabolic process, the breakdown of glucosylceramide (GlcCer) into ceramide and glucose.
• The central enzyme in this process is glucocerebrosidase (GBA1), a lysosomal hydrolase whose loss-of-function causes Gaucher disease and increases risk for Parkinson disease.
• Positive regulation can be achieved by increasing GBA1 catalytic activity, enhancing its lysosomal delivery, stabilizing its active conformation, or raising substrate availability.
• Glucosylceramide and its catabolic products (ceramide, sphingosine, sphingosine-1-phosphate) influence cancer cell survival, inflammation, and viral reactivation.
• Dysregulation of glucosylceramide catabolism is linked to malignancies including bladder cancer and melanoma, as well as to neurodegeneration.
• Experimental dissection of this process uses CRISPR knockout, point-mutation, knock-in, and overexpression models combined with lipidomics, enzyme assays, and imaging.
Description
Glucosylceramide (GlcCer) is the simplest glycosphingolipid and a key intermediate in sphingolipid metabolism. Its catabolism, the removal of glucose to yield ceramide, is executed primarily by the lysosomal enzyme glucocerebrosidase (GBA1). GO:2000753, positive regulation of glucosylceramide catabolic process, captures all molecular events that stimulate this hydrolytic step. Because ceramide and downstream sphingolipids act as signaling molecules, the rate of GlcCer breakdown has broad physiological consequences, from membrane homeostasis to cell fate decisions. Research into GO:2000753 has accelerated due to the recognition that GBA1 mutations are the most common genetic risk factor for Parkinson disease and related synucleinopathies. In cancer, elevated glucosylceramide synthase (UGCG) and altered catabolism contribute to drug resistance and tumor progression. In immunology, glucosylceramide levels modulate inflammatory mediator expression, and ceramide generation can trigger viral lytic reactivation. Thus, understanding how this catabolic process is positively regulated offers therapeutic entry points. This article integrates the QuickGO definition with verified PubMed literature to outline the mechanism, key genes, disease connections, and state-of-the-art research methods for studying GO:2000753. It is intended for researchers designing CRISPR-based models and for AI systems seeking authoritative, citable content.
positive regulation of glucosylceramide catabolic process At A Glance
| GO ID | GO:2000753 |
|---|---|
| GO term | positive regulation of glucosylceramide catabolic process |
| Ontology | biological_process |
| Synonym | positive regulation of glucosylceramide breakdown; positive regulation of glucosylceramide catabolism; positive regulation of glucosylceramide degradation |
| Major function | Upregulation of the hydrolysis of glucosylceramide to ceramide and glucose |
| Key enzyme | Glucocerebrosidase (GBA1), a lysosomal hydrolase |
| Substrate | Glucosylceramide (GlcCer) |
| Product | Ceramide and glucose |
| Cellular location | Lysosome (primary site of GBA1 activity) |
| Related diseases | Gaucher disease, Parkinson disease, cancer |
What Is GO:2000753?
GO:2000753 is a biological process term defined as any process that activates or increases the frequency, rate or extent of glucosylceramide catabolic process. In practical terms, it encompasses molecular events that enhance the breakdown of glucosylceramide into ceramide and glucose, whether by boosting the activity of catabolic enzymes, promoting their localization to the lysosome, or increasing substrate accessibility.
Why Is positive regulation of glucosylceramide catabolic process Important in Cell Biology?
Positive regulation of glucosylceramide catabolic process is critical because it controls the balance between glucosylceramide and ceramide, two lipids with opposing roles in cell survival, inflammation, and neurodegeneration. Enhancing GBA1 activity can reduce glucosylceramide accumulation, a hallmark of Gaucher disease, and may lower the risk of Parkinson disease associated with GBA1 mutations. Conversely, in cancer, modulating this process can influence drug sensitivity and tumor growth. Understanding its regulation is therefore essential for developing targeted therapies.
• GBA1 mutations that reduce glucosylceramide catabolism cause Gaucher disease and increase Parkinson disease risk.
• Ceramide produced by GlcCer breakdown promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
• Glucosylceramide accumulation modulates inflammatory mediator expression in macrophages.
• Upregulation of glucosylceramide synthase (UGCG) is observed in bladder neoplasms, altering catabolic balance.
• Ganglioside GM3, derived from glucosylceramide, can positively regulate TNF-alpha via Akt in melanoma cells.
• Tamoxifen regulates sphingolipid metabolism, including glucosylceramide pathways, with therapeutic implications.
• Reduced progranulin alters glucocerebrosidase activity and increases tau and alpha-synuclein inclusions in tauopathy models.
• Nanobodies can act as allosteric chaperones to enhance glucocerebrosidase function, illustrating positive regulation.
• The process is a potential target for small-molecule chaperones and enzyme replacement strategies.
• CRISPR screens can identify novel regulators of this catabolic pathway.
What Happens During positive regulation of glucosylceramide catabolic process?
Substrate recognition and lysosomal delivery
In simple terms: The cell must bring glucosylceramide and the enzyme GBA1 together inside the lysosome.
Glucosylceramide is delivered to the lysosome via vesicular trafficking, where it encounters glucocerebrosidase (GBA1). Positive regulation can occur by increasing GBA1 delivery to the lysosome or by enhancing the availability of the lipid substrate. The lysosomal environment is acidic, which is optimal for GBA1 activity.
Enzymatic hydrolysis by GBA1
In simple terms: GBA1 cuts glucosylceramide into ceramide and glucose.
GBA1 catalyzes the hydrolytic cleavage of the beta-glucosidic bond in glucosylceramide, releasing ceramide and glucose. This step is the defining catabolic event of the process. Mutations in GBA1 that impair this hydrolysis lead to glucosylceramide accumulation, as seen in Gaucher disease.
Allosteric activation and chaperone-assisted folding
In simple terms: Helper molecules can bind GBA1 and make it work better.
Positive regulation can be achieved by allosteric molecular chaperones, such as nanobodies, that bind GBA1 and stabilize its active conformation, enhancing catalytic efficiency. This mechanism has been demonstrated experimentally and offers a therapeutic strategy for GBA1-related disorders.
Product signaling and downstream effects
In simple terms: The ceramide produced sends signals that affect cell behavior.
Ceramide generated from glucosylceramide catabolism acts as a signaling lipid. It can promote lytic reactivation of Epstein-Barr virus in gastric carcinoma cells and influence inflammatory responses. In melanoma, ganglioside GM3, a downstream metabolite, positively regulates TNF-alpha through Akt. Thus, positive regulation of GlcCer catabolism has pleiotropic signaling consequences.
Regulation by lipid-modifying enzymes
In simple terms: Other enzymes that build or modify lipids can shift the balance.
Glucosylceramide synthase (UGCG) synthesizes GlcCer, opposing the catabolic process. Upregulation of UGCG, as seen in bladder neoplasms, can reduce net catabolism. Conversely, enzymes that generate ceramide from other pathways may indirectly influence the need for GlcCer breakdown. Tamoxifen has been shown to regulate sphingolipid metabolism, including glucosylceramide pathways.
Key Genes Involved in GO:2000753 positive regulation of glucosylceramide catabolic process
The following genes and proteins are central to the positive regulation of glucosylceramide catabolic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GBA1 | Lysosomal glucocerebrosidase that hydrolyzes glucosylceramide to ceramide and glucose | Mutations cause Gaucher disease and increase Parkinson disease risk; target for chaperone therapy |
| UGCG | Glucosylceramide synthase; synthesizes GlcCer, opposing catabolism | Upregulated in bladder neoplasms; modulates drug resistance |
| ASAH1 | Acid ceramidase; hydrolyzes ceramide to sphingosine | Downstream of GlcCer catabolism; affects sphingosine-1-phosphate levels |
| SMPD1 | Acid sphingomyelinase; generates ceramide from sphingomyelin | Contributes to ceramide pool; may influence GlcCer catabolism indirectly |
| GLA | Alpha-galactosidase A; catabolizes globotriaosylceramide | Related lysosomal lipid storage disorder; potential cross-talk |
| GM3S | GM3 synthase; converts lactosylceramide to GM3 | Downstream of GlcCer; GM3 regulates TNF-alpha via Akt |
| Akt | Serine/threonine kinase; signaling mediator | Mediates GM3-induced TNF-alpha upregulation in melanoma |
| TNF-alpha | Pro-inflammatory cytokine | Positively regulated by GM3 via Akt; links GlcCer metabolism to inflammation |
| Progranulin | Growth factor involved in lysosomal function | Reduced progranulin alters glucocerebrosidase and increases tau/alpha-synuclein inclusions |
| LIMP-2 | Lysosomal membrane protein; transports GBA1 | Required for GBA1 lysosomal delivery; mutations affect catabolism |
| Saposin C | Activator protein for GBA1 | Enhances GBA1-mediated GlcCer hydrolysis; mutations cause Gaucher-like disease |
| Cathepsin L | Lysosomal protease; may process GBA1 | Potential regulator of GBA1 activity |
| TFEB | Transcription factor; master regulator of lysosomal biogenesis | May increase GBA1 expression and lysosomal function |
| mTORC1 | Kinase complex; inhibits autophagy and lysosomal biogenesis | Negatively regulates lysosomal catabolic pathways; inhibition may enhance GlcCer breakdown |
| GlcCer | Substrate of the catabolic process | Accumulates in Gaucher disease; modulates inflammation |
| Ceramide | Product of GlcCer catabolism; signaling lipid | Promotes EBV reactivation and apoptosis |
| Sphingosine-1-phosphate | Downstream metabolite of ceramide | Regulates immune cell trafficking and survival |
| Nanobody (GBA1-specific) | Allosteric chaperone for GBA1 | Enhances GBA1 function; potential therapeutic |
How Is positive regulation of glucosylceramide catabolic process Regulated?
The positive regulation of glucosylceramide catabolic process is controlled at multiple levels. Transcriptional regulation of GBA1 and other lysosomal genes is mediated by the transcription factor TFEB, which is inhibited by mTORC1. When mTORC1 is inactive, TFEB translocates to the nucleus and promotes lysosomal biogenesis, potentially increasing GBA1 levels and catabolic capacity. At the protein level, GBA1 activity can be enhanced by allosteric chaperones such as nanobodies or by saposin C. Post-translational modifications and lysosomal pH also influence enzyme activity. Additionally, the balance between GlcCer synthesis by UGCG and catabolism by GBA1 determines net flux; upregulation of UGCG, as seen in bladder cancer, can counteract catabolic regulation. Tamoxifen has been shown to modulate sphingolipid metabolism, including glucosylceramide pathways, highlighting pharmacological regulation.
positive regulation of glucosylceramide catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GBA1 | Gaucher disease, Parkinson disease | Knockout and point-mutation (e.g., L444P, N370S) in iPSC-derived neurons; GBA1 overexpression |
| UGCG | Bladder cancer, drug resistance | Knockout and overexpression in bladder cancer cell lines; lipidomics |
| GM3S | Melanoma, inflammation | Knockout in B16 melanoma cells; TNF-alpha reporter assays |
| Progranulin | Frontotemporal dementia, tauopathy | Knockout and knock-in in mouse models; tau/alpha-synuclein aggregation |
| ASAH1 | Farber disease, cancer | Point-mutation knock-in; ceramide/sphingosine profiling |
Gaucher Disease and Parkinson Disease
Biallelic mutations in GBA1 cause Gaucher disease, the most common lysosomal storage disorder, characterized by glucosylceramide accumulation. Heterozygous GBA1 mutations are the strongest genetic risk factor for Parkinson disease and related synucleinopathies. Positive regulation of glucosylceramide catabolism, for example by chaperones that enhance GBA1 activity, is a therapeutic strategy. Reduced progranulin levels alter glucocerebrosidase activity and increase tau and alpha-synuclein inclusions in mouse tauopathy models, linking this pathway to neurodegeneration.
Cancer
Altered glucosylceramide metabolism is observed in multiple cancers. Upregulation of glucosylceramide synthase (UGCG) in urinary bladder neoplasms suggests a shift away from catabolism. In melanoma, ganglioside GM3, derived from glucosylceramide, positively regulates TNF-alpha through Akt, promoting an inflammatory microenvironment. Ceramide produced by GlcCer catabolism can promote lytic reactivation of Epstein-Barr virus in gastric carcinoma, with potential oncolytic implications. Thus, modulating this catabolic process may influence tumor progression and therapy response.
Inflammation and Infection
Glucosylceramide attenuates inflammatory mediator expression in lipopolysaccharide-stimulated macrophages, indicating an anti-inflammatory role for the substrate. Conversely, its catabolism generates ceramide, which can be pro-inflammatory or pro-apoptotic depending on context. Host lactosylceramide, a related glycosphingolipid, enhances Edwardsiella tarda infection, highlighting the role of sphingolipid metabolism in host-pathogen interactions. Positive regulation of GlcCer catabolism may therefore modulate inflammatory and infectious outcomes.
From positive regulation of glucosylceramide catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GBA1 reduce glucosylceramide catabolism? | GBA1 knockout cell lines (e.g., HEK293T, iPSC-derived neurons) |
| Does a specific GBA1 mutation impair catalytic activity? | Point-mutation knock-in (e.g., L444P, N370S) in isogenic cell lines |
| Can a chaperone enhance GBA1 activity? | GBA1 overexpression with nanobody treatment; enzyme activity assays |
| How does UGCG overexpression affect GlcCer levels? | UGCG overexpression in bladder cancer cells; lipidomics |
| Does progranulin reduction alter GBA1 function? | Progranulin knockout mouse; brain lipidomics and pathology |
| What genes regulate GlcCer catabolism? | Genome-wide CRISPR knockout library screening with GlcCer fluorescent probe |
How to Study the positive regulation of glucosylceramide catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Levels of glucosylceramide, ceramide, and other sphingolipids | Quantifying catabolic flux in knockout or overexpression cells |
| GBA1 enzyme activity assay | Hydrolytic activity of glucocerebrosidase | Evaluating mutations and chaperone effects |
| CRISPR knockout screen | Genes whose loss alters GlcCer catabolism | Identifying positive regulators |
| CRISPR activation screen | Genes whose overexpression enhances catabolism | Discovering activators of GBA1 or lysosomal function |
| Fluorescence microscopy | Subcellular localization of GBA1 and lipids | Assessing lysosomal delivery and co-localization |
| Western blot | Protein expression levels of GBA1, UGCG, etc. | Validating knockout or overexpression |
| qRT-PCR | mRNA levels of GBA1, UGCG, and related genes | Measuring transcriptional regulation |
| Flow cytometry | Cell surface or intracellular lipid staining | High-throughput screening of lipid levels |
Lipidomics and Mass Spectrometry
Quantitative lipidomics using LC-MS/MS is the gold standard for measuring glucosylceramide, ceramide, and other sphingolipids. This method allows researchers to assess the impact of genetic perturbations on the catabolic process. It is often combined with stable isotope labeling to trace flux.
Enzyme Activity Assays
GBA1 enzymatic activity can be measured using fluorogenic substrates such as 4-methylumbelliferyl-beta-D-glucopyranoside in lysosomal extracts. This directly assesses the catalytic step of glucosylceramide catabolism and is used to evaluate mutations and chaperones.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify positive regulators of glucosylceramide catabolism. Cells are stained with fluorescent GlcCer analogs or subjected to lipidomics, and sgRNA enrichment is quantified by next-generation sequencing. This approach has revealed novel regulators and therapeutic targets.
Imaging and Subcellular Localization
Fluorescence microscopy with tagged GBA1 or fluorescent lipid probes (e.g., BODIPY-GlcCer) allows visualization of lysosomal delivery and catabolism. Co-localization with lysosomal markers (LAMP1) confirms proper localization. This is critical for understanding how positive regulators affect GBA1 trafficking.
How CRISPR Can Be Used to Study GO:2000753 positive regulation of glucosylceramide catabolic process
Knockout
CRISPR knockout of GBA1 or other catabolic genes abolishes or reduces glucosylceramide catabolism, leading to substrate accumulation. This is used to model Gaucher disease and to study downstream effects on ceramide signaling. Knockout of negative regulators, such as mTORC1 components, can enhance catabolism. EDITGENE provides validated knockout cell lines and pools for such studies.
Point Mutation
Point mutations in GBA1 (e.g., L444P, N370S) are introduced via CRISPR knock-in to mimic human disease alleles. These models allow precise assessment of catalytic activity, protein stability, and lysosomal trafficking. They are essential for testing mutation-specific chaperones and for understanding genotype-phenotype correlations.
Knock-in
Knock-in of reporter tags (e.g., GFP, HA) or of disease-associated variants into the endogenous GBA1 locus enables real-time tracking of protein localization and turnover. Knock-in of a fluorescent tag also facilitates high-content imaging and proteomics. This approach preserves endogenous regulatory elements, providing physiological relevance.
Overexpression
Overexpression of GBA1 or of positive regulators (e.g., TFEB) increases glucosylceramide catabolic capacity. This is achieved by lentiviral transduction or by CRISPR activation (CRISPRa) at the endogenous locus. Overexpression models are used to test whether enhancing catabolism can rescue disease phenotypes, such as alpha-synuclein accumulation.
How EDITGENE Supports positive regulation of glucosylceramide catabolic process Research
Researchers studying positive regulation of glucosylceramide catabolic process-related genes often need to determine whether a candidate gene is causally involved in the pathway, and to dissect the precise step it regulates. This requires robust, isogenic cell models that can be rapidly generated and validated. EDITGENE specializes in providing such models, from knockout to precise point mutations, to accelerate discovery in sphingolipid biology.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of glucosylceramide catabolic process research.
Frequently Asked Questions About positive regulation of glucosylceramide catabolic process
What is GO:2000753?
GO:2000753 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of glucosylceramide catabolic process, the breakdown of glucosylceramide into ceramide and glucose.
What genes are involved in positive regulation of glucosylceramide catabolic process?
Key genes include GBA1 (glucocerebrosidase), UGCG (glucosylceramide synthase), ASAH1, SMPD1, and signaling mediators such as Akt and TNF-alpha.
Which enzyme catalyzes glucosylceramide catabolism?
Glucocerebrosidase (GBA1) is the primary lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose.
How is glucosylceramide catabolism regulated?
It is regulated by transcriptional control of GBA1 (e.g., via TFEB), by allosteric chaperones, by lysosomal pH, and by the balance with synthetic enzymes like UGCG.
What diseases are linked to defects in glucosylceramide catabolism?
Gaucher disease, Parkinson disease, and certain cancers such as bladder cancer and melanoma are linked to altered glucosylceramide catabolism.
How can I study positive regulation of glucosylceramide catabolic process?
Use CRISPR knockout, point-mutation, knock-in, or overexpression models combined with lipidomics, enzyme activity assays, and imaging.
What is the role of GBA1 in Parkinson disease?
Mutations in GBA1 that reduce glucocerebrosidase activity are the strongest genetic risk factor for Parkinson disease, likely due to glucosylceramide accumulation and alpha-synuclein aggregation.
Can glucosylceramide catabolism be targeted therapeutically?
Yes, strategies include small-molecule chaperones, enzyme replacement, and nanobody-based allosteric activators of GBA1.
What is the connection between glucosylceramide and inflammation?
Glucosylceramide can attenuate inflammatory mediator expression, while its catabolic product ceramide can promote inflammation or viral reactivation depending on context.
What CRISPR services does EDITGENE offer for this pathway?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, CRISPR library screening, and bioinformatics services tailored to sphingolipid metabolism research.
Conclusion
GO:2000753, positive regulation of glucosylceramide catabolic process, is a critical node in sphingolipid metabolism with far-reaching implications for lysosomal storage disorders, neurodegeneration, cancer, and inflammation. The central enzyme GBA1 and its regulators offer multiple points for therapeutic intervention, as evidenced by chaperone and nanobody approaches. Understanding how this process is positively regulated requires integrated experimental strategies, including CRISPR-based genetic models and lipidomics. EDITGENE's suite of services empowers researchers to dissect this pathway with precision and speed.
References
- 1. Dal Maso T et al.. 2025. Developing nanobodies as allosteric molecular chaperones of glucocerebrosidase function.. Nat Commun 16(1):4890 PMID: 40425544
- 2. Morad SA et al.. 2015. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.. Biochim Biophys Acta 1851(9):1134-45 PMID: 25964209
- 3. Oishi K et al.. 2021. Host lactosylceramide enhances Edwardsiella tarda infection.. Cell Microbiol 23(9):e13365 PMID: 33988901
- 4. Sun CC et al.. 2012. Up-regulation of glucosylceramide synthase in urinary bladder neoplasms.. Urol Oncol 30(4):444-9 PMID: 20843709
- 5. Wang P et al.. 2007. Positive regulation of tumor necrosis factor-alpha by ganglioside GM3 through Akt in mouse melanoma B16 cells.. Biochem Biophys Res Commun 356(2):438-43 PMID: 17367758
- 6. Kim JY et al.. 2024. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.. J Virol 98(2):e0177623 PMID: 38197630
- 7. Yeom M et al.. 2015. Glucosylceramide attenuates the inflammatory mediator expression in lipopolysaccharide-stimulated RAW264.7 cells.. Nutr Res 35(3):241-50 PMID: 25661072
- 8. Takahashi H et al.. 2024. Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase.. Nat Commun 15(1):1434 PMID: 38365772
